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BACKGROUND: Melanoma incidence has increased rapidly in the last decades, and predictions show a continuing increase in the years
to come. The aim of this study was to assess trends in melanoma incidence, Breslow thickness (BT), and melanoma survival among
young and elderly patients in the Netherlands.
METHODS: Patients diagnosed with invasive melanoma between 1994 and 2008 were selected from the Netherlands Cancer Registry.
Incidence (per 100 000) over time was calculated for young (o65 years) and elderly patients (X65 years). Distribution of BT for
young and elderly males and females was assessed. Regression analysis of the log-transformed BT was used to assess changes over
time. Relative survival was calculated as the ratio of observed survival to expected survival.
RESULTS: Overall, 40 880 patients were included (42.3% male and 57.7% female). Melanoma incidence increased more rapidly among
the elderly (5.4% estimated annual percentage change (EAPC), Po0.0001) than among younger patients (3.9% EAPC, Po0.0001).
The overall BT declined significantly over time (Po0.001). Among younger patients, BT decreased for almost all locations. Among
elderly males, BT decreased for melanomas in the head and neck region (P¼ 0.001) and trunk (Po0.001), but did not decrease
significantly for the other regions. Among elderly females, BT only decreased for melanomas at the trunk (P¼ 0.01). The relative
survival of elderly patients was worse compared with that of younger patients (Po0.001).
CONCLUSION: Melanoma incidence increases more rapidly for elderly than for younger patients and the decline in BT is less prominent among
elderly patients than among young patients. Campaigns in the Netherlands should focus more on early melanoma detection in the elderly.
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The incidence of cutaneous melanoma has increased in the last
decades and estimates predict a continuing increase in the coming
years (De Vries et al, 2005). High incidence rates are found in
populations of predominantly European origin, with white
populations in Australia and New Zealand having the highest
incidence rates and Asian and Black populations having the lowest
(Parkin et al, 1997).
In Australia, despite of rising incidence rates, mortality rates
seem to have reached a plateau, possibly because of the fact that
most newly diagnosed melanomas are thinner melanomas, which
usually do not lead to death (Giles et al, 1996).
The most important risk factors for melanoma still are increased
exposure to the sun and sunburns during childhood. Significantly
increased melanoma risk is associated with sun-bed and sun-lamp
exposure (Bulliard, 2000; Gallagher et al, 2005).
In the Netherlands, the total number of melanoma patients is
expected to increase from 2400 patients in 2000 to 4800 patients in
2015, and reached 3500 patients in 2005 (De Vries et al, 2005).
In contrast with Australia, this increase in incidence rate is
accompanied by a rising mortality rate.
Several influences, such as increased melanoma awareness and
an increased life expectancy, might cause a rising incidence of
melanoma. Also, in order to get a vague idea about the true
increase in the incidence of melanoma, it is essential to know how
many pigmented lesions are excised. Marks et al (1997) concluded
that ‘Among people aged 21–40 years the ratio of benign naevi to
melanomas among excised lesions was 27.2, compared to 1.4 in
those aged 60 years and over.’ Thus, the increase in incidence in
the elderly cannot be explained by overtreatment.
Besides, because incidence of melanomas among all Breslow
thickness (BT) categories increased, as well as the mortality rates,
the melanoma epidemic in the Netherlands seems to be real and
not due overdiagnosis (Hollestein et al, 2012).
Various studies have already shown that the melanoma
incidence and mortality among elderly individuals (465 years)
is growing rapidly (Armstrong and Kricker, 1994; Gaudette and
Gao, 1998). As the geriatric population increases in most
industrialised nations (life expectancy almost doubled during the
last century), melanoma will become an important health issue for
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the elderly age group in this century (Kelly, 1998; Chang et al,
2003; Testori et al, 2009).
The most important predictors of mortality, included in the
American Joint Committee on Cancer (AJCC) staging, are tumour
characteristics such as BT, ulceration, mitotic rate, and the
presence of metastases (Balch et al, 2001; Francken et al, 2004).
However, BT has been shown to be the single most important
prognostic factor for survival (De Vries et al, 2007). Therefore, the
main aim of this study was to assess differences in BT and survival
between young and elderly patients with invasive melanoma in the
Netherlands between 1994 and 2008.
MATERIAL AND METHODS
Patients
Patients diagnosed with invasive melanoma between 1994 and 2008
were selected from the Netherlands Cancer Registry, which covers
all patients in the Netherlands. The nationwide Dutch network and
registry of histopathology and cytopathology (PALGA) regularly
submits reports of all diagnosed malignancies to the cancer
registries. The national hospital discharge databank, which
receives discharge diagnoses of admitted patients from all Dutch
hospitals, completes case ascertainment. After notification, well-
trained registry personnel collect data on diagnosis, staging, and
treatment from the medical records, including pathology and
surgery reports, using the registration and coding manual of the
Dutch Association of Comprehensive Cancer Centres. For the
present study, patients with their first primary melanoma were
selected. Stage was defined according to the AJCC staging system.
The study was approved by the local medical ethics committee.
Statistical analysis
Incidence of invasive melanoma per 100000 Dutch individuals was
calculated for young (younger than 65 years) and elderly (65 years
and older) patients in the Netherlands. Because BT measurement was
missing for 9.5% of patients, we used multiple imputation (five
imputations) to generate a complete data set. A model was built that
included sex, location, stage, year of diagnosis, age, and status as
predictors to assess the patients with missing BT measurements.
Median BT was calculated according to sex, age, and localisation, as
well as Breslow distribution over time. Because the TNM Classifica-
tion of Malignant Tumours changed in 2003, stage distribution
before and after 2003 was not comparable and therefore a composite
stage variable was not used in the analysis. The BT was divided
according to the AJCC staging system into the following size
categories: p1.0, 1.0–2.0, 2.0–4.0, and 44.0mm. Patients with an
unknown primary were excluded from the analysis.
The BT distributions for young and elderly males and females were
assessed over time. Because BT is skewed toward smaller tumours
(most melanomas are p1.0mm), BT was log-transformed. A
regression analysis was modelled with log (Breslow) to assess the
changes over the years of incidence according to age, sex, and location.
Vital status and date of last follow-up were established either
directly from the patient’s medical record or through linkage of
cancer registry data with municipal population registries (follow-
up until 1 January 2009), which record information on vital status.
Relative survival is the preferred way to describe the prognosis of
(elderly) patients with melanoma, as it takes into account the risk
of dying from causes other than melanoma. Relative survival was
calculated as the ratio of the observed survival among cancer
patients to the survival that would have been expected based on the
corresponding general population (with respect to age, sex, and
year of diagnosis). National lifespan tables were used to estimate
expected survival (Ederer II method). Relative excess risks (RERs)
of death for year of diagnosis were estimated using a Poisson
regression model.
RESULTS
This study includes 40 880 patients diagnosed with melanoma
between 1994 and 2008. Table 1 depicts the characteristics
of the melanoma patients in the Netherlands between 1994 and
2008, of which 42% were male and 58% were female (Table 1).
The median age was 54 years (range 0–105 years). The trunk was
the most frequently involved melanoma site (36%). From 1994
to 1996, 5907 new melanoma patients were diagnosed (15%),
increasing to 11 023 (27%) in the period from 2006 to 2008.
Almost one-half (49%) of newly diagnosed melanoma patients
had a BT p1.0mm, whereas for 12%, the BT was 44.0mm for
thick melanomas.
Melanoma incidence increased more rapidly among elderly
patients (X65 years) than among younger patients (Figure 1).
In 1994, melanoma incidence was 189 among elderly patients and
144 among younger patients, and in 2008, these numbers increased
to 362 and 241, respectively. The estimated annual percentage
change for young patients was 3.9% (Po0.0001) and for the elderly
was 5.4% (Po0.0001). Especially since 2002, melanoma incidence
appears to be increasing at a faster rate among the elderly than
among their younger counterparts.
Figure 2 shows the proportion of patients that were diagnosed
with thin, median, and thick melanomas over time. The percentage
of young patients with a thick melanoma (Breslow 44.0mm) has
declined over time (Figure 2). In 1994, 16% of males and 10% of
females had a thick melanoma; by 2008, these incidences had
declined to 9% and 5%, respectively (Po0.001).
A decline was also observed among the elderly population, and
especially among elderly females, although it was not as preci-
pitous as among young patients. In 1994, 25% of elderly males
and 20% of elderly females had a thick melanoma, compared with
Table 1 Characteristics of melanoma patients in the Netherlands,
1994–2008
Original data Multiple imputation
Characteristic N % %
Sex
Male 17 305 42.3 42.3
Female 23 575 57.7 57.7
Age
p40 years 9378 23.0 23.0
41–54 years 11 506 28.1 28.1
55–64 years 8217 20.1 20.1
X65 years 11 779 28.8 28.8
Location
Head and neck 5612 13.7 13.7
Trunk 14 693 35.9 35.9
Upper extremities 8163 20.0 20.0
Lower extremities 12 246 30.0 30.0
Other 166 0.4 0.4
Year
1994–1996 5907 14.5 14.5
1997–1999 6720 16.4 16.4
2000–2002 7779 19.0 19.0
2003–2005 9451 23.1 23.1
2006–2008 11 023 27.0 27.0
Breslow category
p1.0mm 19 325 47.3 48.7
1.0–2.0mm 8622 21.1 22.7
2.0–4.0mm 5598 13.7 16.7
44.0mm 3451 8.4 11.9
Unknown 3884 9.5
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19% and 18%, respectively, in 2008 (Po0.001). Although younger
patients generally had thinner melanomas than elderly patients,
the proportion of thin melanomas increased in both age groups. In
1994, 43% of young males and 53% of young females had a thin
melanoma (Breslow p1.0mm); these numbers increased to 51%
and 62%, respectively, in 2008. In 1994, 31% of elderly males and
34% of elderly females had a thin melanoma, compared with 40%
and 42%, respectively, in 2008 (Po0.001).
Table 2 depicts the changes in BT over time according to age,
sex, and location. The BT significantly decreased over time for
head and neck, trunk, and upper extremities among young males
(Po0.001), and for trunk, upper extremities, and lower extremities
among young females (Po0.001) (Table 2). However, among
elderly males, a significant decrease in BT over the years was only
observed for melanomas in the head and neck (P¼ 0.001) and
trunk (Po0.001), and for elderly females, a decrease in BT is noted
only on the trunk (P¼ 0.01).
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Figure 2 Distribution of BT over time among young and elderly patients.
Table 2 Changes in Breslow thickness (log transformation) over time
according to age, sex, and lesion location
Regression coefficient (95% CI) P-value
Young
Males
Head and neck  0.43  0.66 to  0.20 o0.001
Trunk  0.26  0.37 to  0.14 o0.001
Upper extremities  0.36  0.56 to  0.16 o0.001
Lower extremities  0.16  0.41 to  0.1 0.2
Females
Head and neck  0.21  0.51 to 0.1 0.2
Trunk  0.31  0.45 to 0.17 o0.001
Upper extremities  0.51  0.70 to  0.32 o0.001
Lower extremities  0.33  0.46 to  0.19 o0.001
Elderly
Males
Head and neck  0.35  0.56 to  0.14 0.001
Trunk  0.42  0.60 to  0.25 o0.001
Upper extremities  0.20  0.47 to 0.1 0.2
Lower extremities  0.28  0.61 to 0.1 0.1
Females
Head and neck  0.18  0.44 to 0.1 0.2
Trunk  0.36  0.62 to  0.10 0.01
Upper extremities  0.15  0.37 to 0.06 0.2
Lower extremities  0.13  0.32 to 0.1 0.2
Overall
Males and females













































Figure 1 Incidence of invasive melanoma among young and elderly
patients.
Breslow thickness in the Netherlands
S Kruijff et al
572










Relative survival is worse among elderly patients than among
patients younger than 65 years (RER 2.1 for elderly patients; 95%
CI 2.0–203; Po0.001) (Table 3). Adjusted for BT, location, sex,
year, lymph node status, and distant metastases, RER remained
higher among the elderly (RER 1.7; 95% CI 1.6–1.8; Po0.001). The
RER for elderly (65 years and older) vs young patients was
significantly worse for the elderly in all BT categories (p1.0,
1.0–2.0, 2.0–4.0, and 44.0mm) and locations (head and neck,
trunk, upper extremities, and lower extremities).
Figure 3 depicts the cumulative relative survival among the
young and elderly melanoma patients.
Cumulative relative survival is significantly worse for elderly
patients (RER 2.1; 95% CI 2.0–2.3; Po0.001).
DISCUSSION
Melanoma incidence increases more rapidly among the elderly
than among younger individuals. Additionally, rising incidence is
accompanied by decreasing BT mainly in younger individuals. The
decrease in melanoma BT was less prominent among the elderly,
which is still frequently diagnosed with thick melanomas. For most
melanoma locations, BT in the elderly has not declined. Especially
in elderly men, the proportion of thick melanomas has declined
only minimally. The high proportion of thick melanomas only
partly explains the worse survival among elderly melanoma
patients; even within several strata of thickness, survival remains
worse among the elderly than among younger patients.
In general, for males and females, young and old, the percentage
of thin melanomas increased over the period 1994–2008. This is
in accordance with trends in several population-based studies in
various other industrialised countries. Lasithiotakis et al (2006), who
studied 1980 patients diagnosed with melanoma in southern Germany
in the period 1976–2003, observed that median BT decreased
steadily during that period (Po0.01). Buettner et al (2005) studied
all 45 483 melanoma patients diagnosed between 1976 and 2000,
and also noted a significant decrease in median BT (Po0.0001).
In our study, the highest proportion of thin melanomas was
observed in young females, a finding that is shared by many other
studies (De Vries et al, 2008). Women are likely more alert to skin
changes, resulting in thinner melanomas at diagnosis. Various studies
have also shown that female patients were more likely to discover
their melanoma or melanoma recurrence by themselves, even when
adjusted for localisation (Koh et al, 1992; Francken et al, 2007).
A trend towards prognostically more favourable melanomas has
been described in the United States, Australia, and Europe, and can
most likely be attributed to increased awareness in the population
leading to earlier detection and treatment (Shafir et al, 1982;
MacKie et al, 1992).
The most prominent finding in our data was that elderly patients
present with significantly thicker melanomas, a phenomenon
described in both Europe and Australia (Hersey et al, 1991; Melia
et al, 1995; Hanrahan et al, 1997; Kelly, 1998; Chang et al, 2003;
Testori et al, 2009; Criscione and Weinstock, 2010).
The question arises: why do elderly individuals fail so
comprehensively to follow the trend of the younger age group
towards early detection? In the first place when it comes to primary
prevention in the elderly, damage as sunburns during childhood
has already occurred. As far as secondary prevention is concerned,
elderly patients have more difficulty recognising or detecting
changes in their skin and therefore delay visits to their general
practitioner (Criscione and Weinstock, 2010). Difficulty in
detecting melanoma could be related to deteriorating vision,
increased isolation, decreased flexibility, and awareness or
possibly a lack of motivation. Another difficulty for elderly
patients is often the development of multiple seborrhoeic keratoses
that may appear similar to melanoma. Additionally, melanomas
are found on the back in 48% of cases in elderly men, which does
not facilitate detection (Kelly, 1998).
Despite physical deterioration, it has been demonstrated that
older people should be very well able to detect skin changes
associated with early melanoma (Hanrahan et al, 1997). This
finding does suggest that public education campaigns and
increased alertness in the context of elderly care might be useful
to encourage the detection of skin changes. Although previous
educational campaigns have been effective at promoting aware-
ness, they have mainly been focused on younger individuals, with a
continuous lack of specific attention directed towards elderly
individuals (Kelly, 1998).
For instance, in the summer of 1989, a public campaign for
melanoma was organised along the Dutch coast. Evaluating the
results, a temporary rise in incidence and a decrease in melanoma
thickness was seen, but the campaign did not improve mortality
rates on short notice. For elderly, it could not be concluded what
the long-term effects are of sun damage (van der Rhee et al, 1999).
Various studies report age as an independent prognostic factor,
perhaps presenting a surrogate for declining host defence
mechanism associated with advancing age (Testori et al, 2009).
Treatment outcome is also influenced negatively, because older
patients often receive a delayed diagnosis or incorrect staging,
possibly due to a reluctance to treat aggressively because of
patients’ co-morbidities or disabilities (Chang et al, 2003; Testori
et al, 2009). Numerous studies have already demonstrated that
elderly patients, especially those over 60 years of age, have a lower
disease-specific survival rate (Cohen et al, 1987; Loggie et al, 1991;
Austin et al, 1994).
Table 3 Relative excess risk (RER) for elderly (65 years and older) vs
young patients, stratified according to Breslow category and lesion location
Stratification
Adjusted RERa
elderly vs young P-value (adjusteda)
Breslow thickness
p1.0mm 1.9 (1.4–2.6) o0.001
1.0–2.0mm 1.6 (1.3–2.0) o0.001
2.0–4.0mm 1.6 (1.4–1.9) o0.001
44.0mm 1.7 (1.5–1.9) o0.001
Location
Head and neck 1.7 (1.5–2.0) o0.001
Trunk 1.7 (1.5–1.8) o0.001
Upper extremities 1.5 (1.3–1.8) o0.001
Lower extremities 2.0 (1.8–2.4) o0.001
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P <0.001
Figure 3 Cumulative relative survival among young and elderly
melanoma patients.
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In Australia, skin cancer has been identified as a national
health priority, and awareness in the population is at a high
level, thanks to health-promotion activities (Rassaby et al, 1983).
In contrast, studies demonstrate that melanoma awareness in
Europe is not at such a high level, and focus has been mainly
on young individuals (Levi et al, 1995). This hypothesis might
explain the high percentage of thick melanomas in the elderly,
which (given the rising incidence) could have been caused by
sun exposure in the era before melanoma became a health
priority.
In conclusion, melanoma incidence has increased much more
rapidly among the elderly than among younger individuals.
Additionally, in contrast to younger patients, in which rising
incidence is accompanied by a decline in BT, elderly patients still
have the highest proportion of thick melanomas and a decline in
BT among the elderly has not yet occurred. More research should
be done in the pathways to the diagnosis of thick melanomas in the
elderly. In this way, custom-made campaigns could be designed to
prevent the ongoing increase of BT in the elderly.
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